Journal article

DIFFERENTIAL-EFFECTS OF A NOVEL NONPEPTIDE ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) IN RAT-LIVER AND VASCULATURE

PA PHILLIPS, J RISVANIS, K ALDRED, LM BURRELL, B BARTHOLOMEUSZ

Clinical Science | PORTLAND PRESS | Published : 1995

Abstract

1. We studied the effects of the non-selective, non-peptide, orally active endothelin (ET) receptor antagonist bosentan (Ro 47-0203) on rat hepatic and mesenteric vascular membrane 125I-ET-1 binding characteristics in vitro and ex vivo (after bosentan by gavage in vivo). 2. Bosentan caused a concentration-dependent competitive inhibition of 125I-ET-1 binding to female rat mesenteric vascular (predominantly ETA receptors) and hepatic (predominantly ETB receptors) membranes in vitro and ex vivo. 3. The time course of the inhibition of binding ex vivo after administration of bosentan in vivo was 1-4h for mesenteric vascular (predominantly ETA receptors) binding and 1-16h for hepatic (predominan..

View full abstract

University of Melbourne Researchers